Xact Kapitalforvaltning’s Sarepta Therapeutics SRPT Stock Holding History

Xact Kapitalforvaltning’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.44M	Hold	14,702	–	–	0.03%	408
2019 Q4	$1.9M	Buy	14,702 +3,100	+27%	+$313K	0.03%	426
2019 Q3	$874K	Hold	11,602	–	–	0.02%	634
2019 Q2	$1.76M	Hold	11,602	–	–	0.04%	404
2019 Q1	$1.38M	Buy	11,602 +900	+8%	+$116K	0.03%	472
2018 Q4	$1.17M	Buy	10,702 +1,200	+13%	+$150K	0.03%	491
2018 Q3	$1.53M	Buy	9,502 +300	+3%	+$41K	0.03%	472
2018 Q2	$1.22M	Buy	9,202 +500	+6%	+$47.2K	0.03%	530
2018 Q1	$645K	Buy	8,702 +2,500	+40%	+$167K	0.01%	700
2017 Q4	$345K	Buy	+6,202	New	+$329K	0.01%	856

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Xact Kapitalforvaltning's SRPT Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Sarepta Therapeutics (SRPT) position steady in Q1 2020 at 14,702 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #408.

Xact Kapitalforvaltning first reported a position in SRPT in Q4 2017 and has held it in 10 quarters since. The position peaked at $1.9M in Q4 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

Xact Kapitalforvaltning held 14,702 shares of Sarepta Therapeutics worth $1.44M as of Q1 2020.
Xact Kapitalforvaltning left its Sarepta Therapeutics share count unchanged in Q1 2020.
Sarepta Therapeutics made up 0.03% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #408 holding.
Xact Kapitalforvaltning first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Sarepta Therapeutics position peaked at $1.9M in Q4 2019.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.